| U.S. FDA approves Gilead triple HIV drug, rival files lawsuit | | | (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's once-daily, triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market. |
| |
| Norovirus outbreak worsens though athletes unaffected | | | PYEONGCHANG (Reuters) - The number of people struck down by a virus causing vomiting and diarrhoea at the Pyeongchang Winter Olympics has more than doubled to 86, though athletes remain unaffected, the Korean Centers for Disease Control and Prevention (KCDC) said. |
| |
| U.S. senators ask FDA to reject Philip Morris' iQOS application | | | WASHINGTON/NEW DELHI (Reuters) - Ten U.S. senators called on the Food and Drug Administration to reject Philip Morris International Inc's application to market its iQOS smoking device as being less risky than cigarettes, according to a letter to the agency's commissioner. |
| |
| GlaxoSmithKline sees light at end of Advair tunnel | | | LONDON (Reuters) - GlaxoSmithKline sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year. |
| |
| | |
